Medical devices, healthcare technology and the business of care
PMA approval · P240006

VARIPULSE Platform (VARIPULSE Catheter; TRUPULSE Generator; Sterile Interface Cable; nGEN Pump)

Biosense Webster, Inc. · Decision date Nov 6, 2024

FDA DECISIONP240006

What did the FDA approve?

FDA records P240006 as an original PMA application. The recorded decision is approval, dated Nov 6, 2024.

FDA approval order statement

Approval for the VARIPULSE Platform (VARIPULSE Catheter; TRUPULSE Generator; Sterile Interface Cable; nGEN Pump). This device is indicated as follows:VARIPULSE CatheterThe VARIPULSE Catheter is indicated for use in catheter based cardiac electrophysiological mapping (stimulating and recording) and, when used with a TRUPULSE Generator, for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation. The catheter provides location information when used with the CARTO 3 System. The device is intended for adults 22 years old and above. TRUPULSE GeneratorThe generator is indicated for use in conjunction with compatible cardiac ablation catheter to deliver pulsed field (PF) ablation during cardiac ablation procedures.Sterile Interface CableThis cable provides a means to connect a Biosense Webster electrophysiology catheter to the appropriate equipment. The cable may be reused subject to the cleaning and sterilization restrictions detailed in Instructions for Use. nGEN PumpThe nGEN Pump is a peristaltic pump designed to work with a compatible irrigation tubing set, either independently or with a compatible generator, to deliver irrigation solution to compatible irrigated catheters.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Nov 6, 2024

FDA source record

Regulatory record facts

Identifier
P240006
Regulatory pathway
Premarket approval application
Product code
QZI
Decision code
APPR
Decision date
Nov 6, 2024
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.

Product code
QZI
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P240006 received

    Application receipt date recorded by FDA.

  2. P240006 · FDA decision

    APPR

  3. P240006/S019 · Related supplement

    VARIPULSE Platform (VARIPULSE Catheter; TRUPULSE Generator; Sterile Interface Cable; nGEN Pump)

  4. P240006/S020 · Related supplement

    VARIPULSE BI-DIRECTIONAL CATHETER

  5. P240006/S018 · Related supplement

    Varipulse Bi-Directional Catheter

Timeline entries are records held by MedtechLedger for P240006. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240006

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementSep 10, 2026FDA
Biosense Webster, Inc.PMA supplementSep 15, 2026FDA
Biosense Webster, Inc.PMA supplementNov 3, 2026FDA

Explore the linked device profile

Other records with product code QZI

Product / regulatory recordCompanyPathwayDecision dateSource
Kardium, Inc.PMA supplementOct 27, 2026FDA
Kardium, Inc.PMA supplementOct 23, 2026FDA
Volt PFA SystemP250022/S002
ABBOTT MEDICALPMA supplementOct 15, 2026FDA
Medtronic, Inc.PMA supplementOct 9, 2026FDA
ABBOTT MEDICALPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biosense Webster, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
31 Technology Dr., Suite 200, Irvine, CA, 91618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records